BIOCODEX
VC Fund
Gentilly, France
Biocodex is an independent multinational pharmaceutical company built on high-standards science and manufacturing, with six decades of proven success.Founded in 1953, the company’s initial focus was gastroenterology featuring a unique probiotic Saccharomyces boulardii CNCM I-745®, the first probiotic drug of its kind that has a positive effecton the gut’s microflora.Today, Biocodex has transformed itself beyond its probiotic drug roots, expanding its portfolio into a multitude of therapeutic areas which include:
- Total investments:
- 2
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries BIOCODEX invests in
Stages BIOCODEX invests in
Countries BIOCODEX invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nicolas Coudurier
|
|||
Investment Focus
Industry
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Nicolas Coudurier
Founder & CEO
|
Founder & CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MRM Health NV
|
MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. | $64.1M / Series B / Sep 04, 2025 | |
|
MRM Health NV
|
MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications. | $64.1M / Series B / Sep 04, 2025 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does BIOCODEX invest in?
BIOCODEX invests primarily in Biotechnology and Pharmaceutical startups, most often at Series B stage. Most of the 2 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact BIOCODEX?
Public channels for BIOCODEX include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BIOCODEX?
The team at BIOCODEX includes Nicolas Coudurier (Founder & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
